PROSION Therapeutics is a German biotech spinoff introducing a radically new class of therapeutics to redefine druggability and ultimately bring tangible benefits to patients. Through our proprietary ProM-technology, we are able to unlock disease-relevant target proteins inside the cell, that were previously considered as unreachable or undruggable. We are supported by the European Commission and a leading European deep-tech investor (Freigeist Capital).